cysteine rich protein 2Genealiases: CRIP · CRP2 · ESP1
Q-omics provides the consensus-scored CRIP2 profile across patient tissues and cancer cell-line models. CRIP2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CRIP2 is differentially expressed in 11, with the highest sampling consensus in LUSC. Additionally, CRIP2 protein abundance shows 25,168 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, LUSC, and LSCC as cancer lineages where CRIP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CRIP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CRIP2 survival associations across molecular data types. CRIP2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CRIP2 RNA expression–survival associations across cancer types. High CRIP2 expression shows unfavorable associations in UVM, LUSC and BLCA, but favorable associations in KIRC, SKCM and ESCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CRIP2 RNA expression.
This table summarizes CRIP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in LUSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for CRIP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CRIP2 shows lower tumor expression in LUSC, KICH, BLCA and LUAD and higher tumor expression in LIHC and BRCA. The LUSC box plot shows higher CRIP2 RNA expression in normal versus tumor tissue (log2 FC = −2.574, t-test p < 0.001).
This table shows molecular features associated with CRIP2 in patient tissues and cancer cell lines. In patient samples, CRIP2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CRIP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and SOFT_TISSUE.
